SLC5A2 and type 1 diabetes mellitus: Phase II–IV clinical trials are investigating the use of GLP-1 RA, DPP-4i, SGLT2i, selective SGLT1 inhibitors, and dual SGLT1/SGLT2 inhibitors as adjuvant insulin therapy for adult patients with T1D.